Revvity, Inc. (RVTY)

Wall Street analysts covering Revvity, Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $121.07 — +2.7% versus the last price of $117.88. Targets reflect analyst opinion, not a guarantee.

4 members of Congress have disclosed trading RVTY — 6 purchases and 1 sale worth an estimated $87,501. Most recent disclosure: May 4, 2026.

RVTY's own executives and directors have made 0 open-market purchases ($0) and 1 sale ($9,306) in the last 90 days, per SEC Form 4 filings. Most recent: Jul 20, 2026.

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Company website ↗

• P/E ratio (55.6) — how many dollars you pay for each $1 of RVTY's yearly profit. That's high, so the market expects strong growth (and you're paying up for it).
• ROE (3.21%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
• Profit margin (8.16%) — of every $1 in sales, this is what's left as profit after all costs.
• Dividend yield (0.24%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.